share_log

Humanigen's Anti-Tumor Ifabotuzumab Notches Positive Phase 1 Results

Humanigen's Anti-Tumor Ifabotuzumab Notches Positive Phase 1 Results

Humanigen的抗肿瘤Ifaotuzumab获得阳性的1期结果
Dow Jones Newswires ·  2021/04/09 19:27

DJ Humanigen's Anti-Tumor Ifabotuzumab Notches Positive Phase 1 Results

DJ Humanigen的抗肿瘤Ifaotuzumab一期结果呈阳性

By Matt Grossman

马特·格罗斯曼(Matt Grossman)著

Humanigen Inc.'s ifabotuzumab drug achieved positive results in a Phase 1 safety and bio-imaging trial in patients with glioblatoma multiforme, the company said Friday.

Humanigen公司周五表示,该公司的ifobtuzumab药物在多形性胶质母细胞瘤患者的一期安全性和生物成像试验中取得了积极的结果。

Glioblatoma multiforme is a type of brain cancer.

多形性胶质母细胞瘤是一种脑癌。

At both doses in the study, ifabotuzumab showed sensitive and specific tumor targeting in all the patients who received it, Humanigen said. The adverse events in the study were readily manageable, the company said.

Humanigen说,在研究中的两种剂量下,ifobtuzumab在所有接受治疗的患者中都显示出敏感和特异的肿瘤靶向。该公司表示,研究中的不良事件很容易控制。

Andrew Scott, the study's principal investigator, said the results support further investigation of the drug's effect on other solid tumors in a Phase 2 study.

该研究的首席研究员安德鲁·斯科特(Andrew Scott)说,这一结果支持在第二阶段研究中进一步研究该药物对其他实体肿瘤的影响。

Write to Matt Grossman at matt.grossman@wsj.com

写信给马特·格罗斯曼(Matt Grossman),电子邮件:matt.grossman@wsj.com

(END) Dow Jones Newswires

(完)道琼通讯社

April 09, 2021 07:27 ET (11:27 GMT)

2021年04月09日07:27(格林尼治标准时间11:27)

Copyright (c) 2021 Dow Jones & Company, Inc.

版权所有(C)2021年道琼斯公司

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发